Clinical and biomarker factors affecting survival in patients with platinum-sensitive relapsed ovarian cancer receiving olaparib monotherapy: a multicenter retrospective study
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource, 1 online resource.
- Sprache
-
Englisch
- Erschienen in
-
Clinical and biomarker factors affecting survival in patients with platinum-sensitive relapsed ovarian cancer receiving olaparib monotherapy: a multicenter retrospective study ; volume:13 ; number:1 ; day:24 ; month:7 ; year:2023 ; pages:1-9 ; date:12.2023
Scientific reports ; 13, Heft 1 (24.7.2023), 1-9, 12.2023
- Urheber
-
Tashiro, Ryota
Kawazoe, Hitoshi
Mamishin, Kanako
Seto, Keisuke
Udagawa, Ryoko
Saito, Yoshimasa
Hashimoto, Hironobu
Shimoi, Tatsunori
Yonemori, Kan
Yonemura, Masahito
Terakado, Hiroyuki
Nishimura, Takahiro
Kawasaki, Toshikatsu
Furukawa, Tetsuya
Nakamura, Tomonori
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41598-023-39224-0
- URN
-
urn:nbn:de:101:1-2023102616413254603221
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:59 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Tashiro, Ryota
- Kawazoe, Hitoshi
- Mamishin, Kanako
- Seto, Keisuke
- Udagawa, Ryoko
- Saito, Yoshimasa
- Hashimoto, Hironobu
- Shimoi, Tatsunori
- Yonemori, Kan
- Yonemura, Masahito
- Terakado, Hiroyuki
- Nishimura, Takahiro
- Kawasaki, Toshikatsu
- Furukawa, Tetsuya
- Nakamura, Tomonori
- SpringerLink (Online service)
Ähnliche Objekte (12)
Exploratory biomarker analysis in the phase III L-MOCA study of olaparib maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer
Results of a randomised Phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer
Long lasting response with trabectedin monotherapy in relapsed metastatic mesenchymal chondrosarcoma
Olaparib synergizes with arsenic trioxide by promoting apoptosis and ferroptosis in platinum-resistant ovarian cancer
Systemic Immune-Inflammation Index Predicts Outcomes in Platinum-Resistant Relapsed Ovarian Cancer
Phase 1 study of isatuximab monotherapy in Chinese patients with relapsed/refractory multiple myeloma
Zanubrutinib monotherapy in relapsed/refractory mantle cell lymphoma: a pooled analysis of two clinical trials
Rechallenge with First-Line Platinum Chemotherapy for Sensitive-Relapsed Small-Cell Lung Cancer
Computational reactive–diffusive modeling for stratification and prognosis determination of patients with breast cancer receiving Olaparib
Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group
Sustained Complete Remission in Multi-Relapsed Primary CNS Lymphoma Treated with Ibrutinib Monotherapy: A Case Report
Olaparib First-Line Maintenance Monotherapy in BRCA-Mutated Epithelial Ovarian Cancer: Descriptive Analysis of the First French Real-World Data Study
Exploratory biomarker analysis in the phase III L-MOCA study of olaparib maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer
Results of a randomised Phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer
Long lasting response with trabectedin monotherapy in relapsed metastatic mesenchymal chondrosarcoma
Olaparib synergizes with arsenic trioxide by promoting apoptosis and ferroptosis in platinum-resistant ovarian cancer
Systemic Immune-Inflammation Index Predicts Outcomes in Platinum-Resistant Relapsed Ovarian Cancer
Phase 1 study of isatuximab monotherapy in Chinese patients with relapsed/refractory multiple myeloma
Zanubrutinib monotherapy in relapsed/refractory mantle cell lymphoma: a pooled analysis of two clinical trials
Rechallenge with First-Line Platinum Chemotherapy for Sensitive-Relapsed Small-Cell Lung Cancer
Computational reactive–diffusive modeling for stratification and prognosis determination of patients with breast cancer receiving Olaparib
Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group
Sustained Complete Remission in Multi-Relapsed Primary CNS Lymphoma Treated with Ibrutinib Monotherapy: A Case Report
Olaparib First-Line Maintenance Monotherapy in BRCA-Mutated Epithelial Ovarian Cancer: Descriptive Analysis of the First French Real-World Data Study
Exploratory biomarker analysis in the phase III L-MOCA study of olaparib maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer
Results of a randomised Phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer
Long lasting response with trabectedin monotherapy in relapsed metastatic mesenchymal chondrosarcoma
Olaparib synergizes with arsenic trioxide by promoting apoptosis and ferroptosis in platinum-resistant ovarian cancer
Systemic Immune-Inflammation Index Predicts Outcomes in Platinum-Resistant Relapsed Ovarian Cancer
Phase 1 study of isatuximab monotherapy in Chinese patients with relapsed/refractory multiple myeloma
Zanubrutinib monotherapy in relapsed/refractory mantle cell lymphoma: a pooled analysis of two clinical trials
Rechallenge with First-Line Platinum Chemotherapy for Sensitive-Relapsed Small-Cell Lung Cancer
Computational reactive–diffusive modeling for stratification and prognosis determination of patients with breast cancer receiving Olaparib
Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group
Sustained Complete Remission in Multi-Relapsed Primary CNS Lymphoma Treated with Ibrutinib Monotherapy: A Case Report